The safety monitoring committee of the European Medicines Agency is to investigate a potential connection between the use of certain Novo Nordisk (NOV: N) products and suicidal thoughts.
The EMA is responding to a small number of cases where patients taking the diabetes med Ozempic (semaglutide) or weight loss drug Saxenda (liraglutide) had thoughts of self harm.
These cases were flagged by the Icelandic Medicines Agency, with the European agency’s Pharmacovigilance Risk Assessment Committee (PRAC) agreeing to discuss the matter, as part of its routine safety review program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze